Growth Metrics

Tandem Diabetes Care (TNDM) Notes Payables (2013 - 2014)

Tandem Diabetes Care posted quarterly Notes Payables of $29.4 million for Q3 2014, little changed on a QoQ basis from $29.4 million in Q2 2014.

Tandem Diabetes Care (TNDM) has 2 years of Notes Payables data on file, last reported at $29.4 million in Q3 2014.

  • For the quarter ending Q3 2014, Notes Payables changed N/A year-over-year to $29.4 million; the trailing twelve-month figure through Sep 2014 stood at $29.4 million (changed N/A YoY), and the FY2013 full-year result was $29.4 million, changed N/A from the prior year.
  • Notes Payables for Q3 2014 stood at $29.4 million, roughly flat from $29.4 million in the prior quarter.
  • Across five years, Notes Payables topped out at $29.4 million in Q1 2014 and bottomed at $29.4 million in Q2 2014.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Tandem Diabetes Care 1.31 Bn 739.55 Mn 136.79 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2014 29.42 Mn
Jun 30, 2014 29.39 Mn
Mar 31, 2014 29.44 Mn
Dec 31, 2013 29.40 Mn